HOOK Company Profile and Key Details

Q: Who are the executives of HOOK?

Mr. Andreas BergthalerCo-FounderMr. Jorn AldagChief Executive Officer & DirectorMr. Joern AldagChief Executive Officer & DirectorProf. Rolf M. Zinkernagel M.D., Ph.D.Co-FounderDr. Roman Necina Ph.D.Chief Devel. OfficerDr. Reinhard Kandera Ph.D.Chief Financial Officer & DirectorMr. Michael SzumeraExecutive Director of CommunicationsMs. Christine D. Baker M.B.A.Chief Operating OfficerMs. Marine PopoffCommunications & Investor Relations Mang.Dr. Klaus Orlinger Ph.D.Chief Scientific OfficerMr. Lukas FlatzCo-FounderMr. Matthew L. S. BeckExecutive Director of Investor Relations

NASDAQ : HOOK

HOOKIPA Pharma

$1.18

-0.005-0.42%

At Close 4:00 PM

70.51

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

HOOKIPA Pharma Inc. (HOOK) stock declined over -0.42%, trading at $1.18 on OTC, down from the previous close of $1.19. The stock opened at $1.20, fluctuating between $1.18 and $1.20 in the recent session.

Stock Snapshot

1.185

Prev. Close

14.77M

Market Cap

1.18

Day Low

-0.24

P/E Ratio

-4.83

EPS (TTM)

-0.62

Cash Flow per Share

1.2

Open

12.52M

Number of Shares

1.2

Day High

79.14%

Free Float in %

0.91

Book Value

4.82K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	1.20	1.20	1.18	1.18	6.38K
Apr 30, 2026	1.12	1.13	1.12	1.13	25.65K
Apr 29, 2026	1.18	1.18	1.12	1.16	29.62K
Apr 28, 2026	1.10	1.15	1.10	1.15	3.51K
Apr 27, 2026	1.10	1.12	1.10	1.12	4.2K
Apr 23, 2026	1.13	1.13	1.10	1.10	6.05K
Apr 22, 2026	1.14	1.16	1.13	1.14	6.47K
Apr 21, 2026	1.15	1.15	1.12	1.14	2.31K
Apr 20, 2026	1.13	1.16	1.12	1.16	1.74K
Apr 17, 2026	1.10	1.15	1.10	1.15	847
Apr 16, 2026	1.10	1.15	1.07	1.15	4.77K
Apr 14, 2026	1.12	1.15	1.07	1.12	53.58K
Apr 13, 2026	1.13	1.15	1.12	1.15	16.34K
Apr 10, 2026	1.15	1.15	1.12	1.14	10.95K
Apr 09, 2026	1.07	1.15	1.07	1.14	25.64K
Apr 08, 2026	1.14	1.15	1.09	1.12	16.29K
Apr 07, 2026	1.09	1.14	1.09	1.14	6.32K
Apr 06, 2026	1.09	1.15	1.09	1.15	5.76K
Apr 02, 2026	1.04	1.15	1.04	1.15	35.94K
Apr 01, 2026	1.05	1.09	1.01	1.09	25.45K

Contact Details

New York City, NY 10118

United States

https://www.hookipapharma.com 431 890 6360

About Company

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

HOOKIPA Pharma Inc. (OTC:HOOK) closed at $1.18 USD, losing -$0.01 (-0.42%) from the previous close of $1.19. The stock is currently mid-range between its 52-week high and low $0.81 and $1.77. With a market capitalization of about $14.77 million, HOOKIPA Pharma Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 11.17 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, HOOKIPA Pharma Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Malte Peters, the company employs approximately 82 people and listed since April 18, 2019. HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.

Technical Performance

HOOK has shown mixed momentum, gaining 4.69% over the past week and -42.76% over the past quarter, though year-to-date performance is down -56.72%. Short-term trend indicators are bullishly aligned (SMA20 -15.42%, SMA50 -31.55%, SMA200 -52.09%). The stock’s 14-day RSI is 21.97 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.15% below its high and over 16.55% above its low. Average 10-day trading volume of 13.87 thousand shares is slightly above the 3-month average of 10.48 thousand, indicating heightened recent market interest.

Valuation Metrics

HOOKIPA Pharma Inc. trades at a P/E ratio of -0.35, slightly below the S&P 500 average, with a price-to-sales ratio of 1.45 and a price-to-book ratio of 0.52 suggesting the stock is closer to book value. The P/FCF stands at -0.53, also below market averages.

Dividend & Fair Value

HOOKIPA Pharma Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.10. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of $0.09. The next quarter is forecast at -$0.64. Next year's EPS is expected at $15.59. HOOKIPA Pharma Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -114.75%. The prior quarter beat by -34.43%. Over the last six quarters, Apple has recorded several small beats. These include -14.06% in November 14, 2024.

Shareholding & Insider Activity

HOOKIPA Pharma Inc. has 9.80 million shares outstanding. The public float is 9.62 million shares, elevated short interest at 0.45% of float. This equals 35.80 thousand shares. The short ratio is 0.57 days. Institutional investors hold 40.8% of the float. Insiders own 19.27%. SOFINNOVA CAPITAL VI FCPR holds 3.18 million shares, Forbion Capital Fund II Cooperatief U.A. has 2.49 million shares and Matushansky Igor has 80.18 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, HOOKIPA Pharma generated $20.13M in revenue, or $0.21 per share. Gross margin was 82.35%, operating margin -421.92%, and net profit margin -405.29%. Returns are negative, with ROA at -50.56% and ROE at -90.79%.
On valuation metrics, HOOKIPA Pharma trades at a P/E of -0.35, P/S of 1.45 and P/B of 0.52. The current ratio is 3.93 and quick ratio is 3.93. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 341.63 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -51.32.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, HOOKIPA Pharma posted revenue of $20.13M, down slightly from $14.25M in the prior quarter. Gross profit was $16.58M (margin 82.35%). Operating income was - $84.93M (margin -421.9%). Net income was- $81.58M (EPS - $0.86).
The company ended the quarter with $117.10M in cash and short-term investments, a total debt of $6.56M, and net debt of - $110.54M. Total assets were $161.34M, with equity of $89.86M. Financials further reflected weakness, with operating cash flow of - $57.52M, free cash flow of - $61.68M, and capital expenditures of - $4.16M.

Price Forecast & Outlook

Our AI price prediction model suggests that HOOKIPA Pharma Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.69%, with price expected at $1.20 by May 18, 2026, within a range of $1.17 to $1.22 3-Month Outlook: Projected fall of -67.8%, reaching $0.38 by July 31, 2026, with a range of $0.33 to $0.43. 1-Year Outlook: Projected gain of 274.58%, with price at $4.42 by May 04, 2027, within a range of $0.00 to $4.30.

Key Takeaways

HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares are down -56.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows HOOKIPA Pharma Inc. trading at a premium to the broader market with a P/E of -0.35. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $11.74, suggesting 894.92% upside. Our AI forecast model points to short-term strength (1.69% over two weeks), a medium-term fall (-67.8% over three months), and a longer-term gain (274.58% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current HOOKIPA Pharma Inc. (HOOK) stock price?

HOOKIPA Pharma Inc. (OTC: HOOK) stock price is $1.18 in the last trading session. During the trading session, HOOK stock reached the peak price of $1.20 while $1.18 was the lowest point it dropped to. The percentage change in HOOK stock occurred in the recent session was -0.42% while the dollar amount for the price change in HOOK stock was - $0.01.

HOOK's industry and sector of operation?

The OTC listed HOOK is part of Biotechnology industry that operates in the broader Healthcare sector. HOOKIPA Pharma Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HOOK?

Mr. Andreas Bergthaler
Co-Founder
Mr. Jorn Aldag
Chief Executive Officer & Director
Mr. Joern Aldag
Chief Executive Officer & Director
Prof. Rolf M. Zinkernagel M.D., Ph.D.
Co-Founder
Dr. Roman Necina Ph.D.
Chief Devel. Officer
Dr. Reinhard Kandera Ph.D.
Chief Financial Officer & Director
Mr. Michael Szumera
Executive Director of Communications
Ms. Christine D. Baker M.B.A.
Chief Operating Officer
Ms. Marine Popoff
Communications & Investor Relations Mang.
Dr. Klaus Orlinger Ph.D.
Chief Scientific Officer
Mr. Lukas Flatz
Co-Founder
Mr. Matthew L. S. Beck
Executive Director of Investor Relations

How HOOK did perform over past 52-week?

HOOK's closing price is 45.5% higher than its 52-week low of $0.81 where as its distance from 52-week high of $1.77 is -33.33%.

How many employees does HOOK have?

Number of HOOK employees currently stands at 82.

Link for HOOK official website?

Official Website of HOOK is: https://www.hookipapharma.com

How do I contact HOOK?

HOOK could be contacted at phone 431 890 6360 and can also be accessed through its website. HOOK operates from 350 Fifth Avenue, New York City, NY 10118, United States.

How many shares of HOOK are traded daily?

HOOK stock volume for the day was 4.82K shares. The average number of HOOK shares traded daily for last 3 months was 11.17K.

What is the market cap of HOOK currently?

The market value of HOOK currently stands at $14.77M with its latest stock price at $1.18 and 12.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	82
Beta	0.82
Sales or Revenue	$20.13M
5Y Sales Change%	-0.974%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

HOOK Company Profile and Key Details

HOOKIPA Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook